Abstract: According to various aspects of the instant disclosure, a rapidly-sedimenting magnetic particle can include a core or inner layer. The core or inner layer can include a ferrimagnetic material and have at least one of a maximum field strength ranging from about 20 emu/g to about 250 emu/g, and a remanence ranging from about 0 cmu/g to about 20 emu/g. The rapidly-sedimenting magnetic particle can further include a coating layer overlaying at least a portion of the core or inner layer. The particle can further include an outer coating layer overlaying at least a portion of the core coating.

Abstract: The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m2/g and have a mean particle size by volume distribution of between about 0.7 ?m and about 8 ?m.

Abstract: Compositions of particles having at least 95% by weight of cisplatin and a specific surface area (8SA) of at least 3.5 m2/g. methods for their use. and methods for their production are provided.

Abstract: Suspensions and their use for treating tumors are provided, where the suspensions include (a) particles of at least 95% by weight of cisplatin, wherein the particles have a specific surface area (SSA) of at least 3.5 m2/g, (b) about 40% to about 60% w/w of glycerin, (c) about 20% to about 40% w/w of propylene glycol, (d) about 5% to about 20% w/w of ethanol, and (e) about 5% to about 10% w/w of 0.9% sodium chloride in water.

Abstract: The disclosure provides compositions and methods for use of compositions that include particles comprising at least 30% niclosamide by weight, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, wherein the particles have one or more of: (i) a mean bulk density (not tapped) of less than 0.40 g/cm3; 00 a mean tapped density of less than 0.55 g/cm 3 ; and/or (in) a specific surface area (SSA) of at least 3.6 m2/g.

Abstract: Particles of at least 95% by weight of sorafenib, or a pharmaceutically acceptable salt thereof are provided, wherein the particles have a specific surface area (SSA) of at least 2 m2/g and have a mean particle size by volume distribution of between about 0.7 ?m and about 8 ?m, as are methods for their use, and methods for making such particles.

Abstract: Compositions of particles having at least 95% by weight of rucaparib and a specific surface area (SSA) of at least 12 m2/g, methods for their use, and methods for their production are provided.

Abstract: Compositions of particles having at least 95% by weight of niraparib and a specific surface area (SSA) of at least 5 m2/g, methods for their use, and methods for their production are provided.

Abstract: Compositions of particles having at least 95% by weight of niraparib and a specific surface area (SSA) of at least 5 m2/g, methods for their use, and methods for their production are provided.

Abstract: Compositions of particles having at least 95% by weight of rucaparib and a specific surface area (SSA) of at least 12 m2/g, methods for their use, and methods for their production are provided.

Abstract: The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m2/g and have a mean particle size by volume distribution of between about 0.7 ?m and about 8 ?m.

Abstract: The disclosure provides particles of at least 95% by weight of sorafenib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 2 m2/g and have a mean particle size by volume distribution of between about 0.7 ?m and about 8 ?m, methods for their use, and methods for making such particles.

Abstract: The disclosure provides particles of at least 95% by weight of lapatinib, or a pharmaceutically acceptable salt thereof, wherein the particles have a specific surface area (SSA) of at least 10 m2/g and have a mean particle size by volume distribution of between about 0.7 ?m and about 8 ?m.

Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.

Abstract: The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections.

Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.

Abstract: The present disclosure relates to ciprofloxacin polymorphs and their use in treating infections.

Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.

Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.

Abstract: Compositions are provided that include having at least 95% by weight of a taxane, or a pharmaceutically acceptable salt thereof, where the particles have a mean bulk density between about 0.050 g/cm3 and about 0.15 g/cm3, and/or a specific surface area (SSA) of at least 18 m2/g, 20 m2/g, 25 m2/g, 30 m2/g, 32 m2/g, 34 m2/g, or 35 m2/g. Methods for making and using such compositions are also provided.